Infliximab (Remicade)

Type: drug

Status: FDA Approved (for other inflammatory conditions)

Developer: Janssen Biotech (now Johnson & Johnson)

Breakthrough Summary

No summary available.

Mechanism of Action

Details pending.

Year: 2026